| abstract |
The present invention relates to a polypeptide comprising a human IL-2 mutein numbered according to wild type IL-2, wherein said human IL-2 is substituted at at least one of positions 20, 88 or 126 Thus, the mutein preferentially activates T cells with respect to NK cells. In particular, D20H and I, N88R, I and R have relative T-cell differential activity much greater than native IL-2, with associated reduced in vivo toxicity as expected. The invention also includes polynucleotides encoding muteins of the invention, vectors containing said polynucleotides, transformed host cells, pharmaceutical compositions comprising said muteins and methods of treatment. |